Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-EN | Version v6-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2021-02-10 | 2021-02-09 |
| Drug Identification Number | 02139529 | 02139529 |
| Brand name | SODIUM ACETATE INJECTION, USP | SODIUM ACETATE INJECTION, USP |
| Common or Proper name | Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL | Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | SODIUM ACETATE | SODIUM ACETATE |
| Strength(s) | 328MG | 328MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 100 mL | 100 mL |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-01-06 | 2021-01-06 |
| Actual start date | ||
| Estimated end date | Unknown | Unknown |
| Actual end date | 2021-02-09 | 2021-02-09 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada Ltd. is pleased to advise that our Sodium Acetate Injection will be removed off allocation effective today, Tuesday, February 9, 2021. The product will be available to all customers without restrictions. | Fresenius Kabi Canada Ltd. is pleased to advise that our Sodium Acetate Injection will be removed off allocation effective today, Tuesday, February 9, 2021. The product will be available to all customers without restrictions. |
| Health Canada comments |